Literature DB >> 24622656

Acarbose: an alternative to metformin for first-line treatment in type 2 diabetes?

Ronald C W Ma1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24622656     DOI： 10.1016/S2213-8587(13)70107-4

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  4 in total

Review 1.  Metformin and metabolic diseases: a focus on hepatic aspects.

Authors:  Juan Zheng; Shih-Lung Woo; Xiang Hu; Rachel Botchlett; Lulu Chen; Yuqing Huo; Chaodong Wu
Journal:  Front Med       Date:  2015-02-12       Impact factor: 4.592

2.  Complete biosynthetic pathway to the antidiabetic drug acarbose.

Authors:  Takeshi Tsunoda; Arash Samadi; Sachin Burade; Taifo Mahmud
Journal:  Nat Commun       Date:  2022-06-15       Impact factor: 17.694

3.  Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke.

Authors:  Yan-Rong Li; Sung-Sheng Tsai; Dong-Yi Chen; Szu-Tah Chen; Jui-Hung Sun; Hung-Yu Chang; Miaw-Jene Liou; Tien-Hsing Chen
Journal:  Cardiovasc Diabetol       Date:  2018-01-04       Impact factor: 9.951

4.  Comparative assessment of the efficacy and safety of acarbose and metformin combined with premixed insulin in patients with type 2 diabetes mellitus.

Authors:  Honghua Wu; Jie Liu; Qingqing Lou; Jing Liu; Li Shen; Mingxia Zhang; Xiaofeng Lv; Mingjun Gu; Xiaohui Guo
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.